Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24)

The summary for the Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24): This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to establish Biospecimen Banks for the NCI National Clinical Trials Network (NCTN; The NCTN Biospecimen Banks will be responsible for collecting, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded Phase III and large Phase II clinical treatment trials. The goal is to support NCTN with the state-of the-art biospecimen banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Banks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Banks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers to ensure effective operation. One of the NCTN banks will be also expected to provide banking services for the NCI Experimental Therapeutics Clinical Trials Network (ETCTN; ETCTN collects biospecimens from cancer patients treated on NCI Phase I and small Phase II clinical trials).
Federal Grant Title: Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-14-501
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.394
CFDA Descriptions: Cancer Detection and Diagnosis Research
Current Application Deadline: Aug 15, 2014
Original Application Deadline: Aug 15, 2014
Posted Date: Jun 5, 2014
Creation Date: Jun 5, 2014
Archive Date: Sep 15, 2014
Total Program Funding: $11,750,000
Maximum Federal Grant Award: $11,750,000
Minimum Federal Grant Award: none
Expected Number of Awards: 5
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following:
Eligibility is limited to an institution/entity that is operating the physical infrastructure of one or more existing Group Banks of human specimens from Phase II and III cancer clinical treatment trials funded under RFA-CA-09-504 (irrespective of whether the actual award under RFA-CA-09-504 was made to this institution/entity or to another institution/entity under the former NCI-sponsored Clinical Trials Cooperative Group Program structure). The eligible institutions may configure themselves at their discretion in terms of location of the biospecimen banking infrastructure (maintaining current or moving to a new location) and/or the selection of the institution/entity submitting the application (which can also be a foundation if it is a recipient of the NCTN Operations Center award under RFA-CA-12-010) for one of the NCTN Groups, as long as a group of institutions applying together is affiliated for biospecimen banking with one and only one NCTN Group funded under RFA-CA-12-010.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Tria...
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
Revisions for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Resear...
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Researc...
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Researc...
Image-Guided Cancer Interventions (STTR [R41/R42])
An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2019